The Alzheimer's Drug Discovery Foundation (ADDF) invites scientists from the biotechnology industry and academia to apply for a grant award program entitled Novel Approaches to Drug Discovery for Alzheimer's Disease. The goal of the research program is to accelerate the discovery, development and clinical evaluation of effective therapies for Alzheimer's disease. This grant program is being made possible through a generous donation from Elan Corporation, plc (NYSE: ELN).
The total pool of grant funds available for fiscal year 2008 is $535,000. Only research programs with lead compounds are eligible. Target discovery and validation programs will not be accepted. Funds may be used for advancing the development of lead compounds through pre-clinical in-vitro and in-vivo evaluation including pharmacology, toxicology, pharmacokinetics, formulation chemistry and the conduct of pre-clinical proof of concept studies. A funding priority is to support AD discovery in emerging biotechnology companies.
Applications are available at www.alzdiscovery.org. The submission deadline date is October 15, 2007. Applications will be reviewed by an independent Scientific Review Committee convened by ADDF and comprised of leading experts in the Alzheimer's drug discovery and development research field and biotechnology investment community. Selections will be made by December 31, 2007 and funding will be awarded in January 2008. Criteria for selection is based on the merit and feasibility of the proposed research and its relevance to drug discovery and development for the treatment of Alzheimer's disease, the qualifications of the scientific staff conducting the study, the excellence of the research environment including the availability of working with a multidisciplinary research team, and the likelihood of advancing the field.
For more information, contact ADDF Executive Director Howard Fillit, MD, at 212-935-2402 or email@example.com.
About the Alzheimer's Drug Discovery Foundation (ADDF)
The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity established in 2004 to expand upon the programs initiated by the Institute for the Study of Aging (ISOA), a private foundation founded by the Lauder family in 1998. Our mission is to accelerate drug discovery research for Alzheimer's disease (AD) through venture philanthropy. To date, ADDF and ISOA have awarded $28.7 million for 195 research programs and conferences worldwide. For more information, visit the ADDF website at www.AlzDiscovery.org.
Elan Corporation, plc (NYSE: ELN) is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Our effort to develop treatment alternatives for patients and caregivers suffering from Alzheimer's disease includes research programs focused on modifying or halting the progression of the disease. Elan shares trade on the New York, London and Dublin Stock Exchanges. For additional information about the company, please visit http://www.elan.com.